Skip to main content
Clinical Trials/NCT05225233
NCT05225233
Recruiting
Not Applicable

Transcranial Direct Current Stimulation (tDCS) With Cognitive Training to Reduce Impulsivity and Weight in Veterans With Obesity: A Clinical Trial

VA Office of Research and Development1 site in 1 country124 target enrollmentNovember 23, 2022
ConditionsObesity

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obesity
Sponsor
VA Office of Research and Development
Enrollment
124
Locations
1
Primary Endpoint
Change in task impulsivity as measured by the NIH Flanker
Status
Recruiting
Last Updated
10 months ago

Overview

Brief Summary

The purpose of this study is to investigate if transcranial direct current stimulation (tDCS) can increase the effectiveness of cognitive training to reduce impulsivity in individuals with obesity, and to evaluate weight change with these individuals. The long-term goal of this research is to develop new treatment approaches for individuals with obesity.

Detailed Description

Two-hundred forty individuals will be screened with the goal of consenting and enrolling up to 124 patients and 88 patients completing the study. Participants completing the study will concurrently complete a structured weight loss program. The investigators' study protocol will consist of 13 study visits including four testing days, one before (V1), one on the day of the tenth session of tDCS (V11), another test visit (V12) 6 weeks later, and a final test visit approximately 4 months after beginning stimulation (V13).

Registry
clinicaltrials.gov
Start Date
November 23, 2022
End Date
April 30, 2026
Last Updated
10 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Veteran enrolled in a MOVE! Weight Management Program (group or individual) at the Minneapolis VA Health Care System
  • Obese (BMI\>30 or BMI\>27 plus at least one weight-related comorbidity)
  • Adults, ages 18 years or older (up to age 80)
  • Able to understand English, self-consent and follow study-related procedures
  • Willing to use a reliable form of birth control if they are of females of child-bearing potential

Exclusion Criteria

  • History of any of the following: seizures, severe or moderate head injury, head surgery, significant neurological disorder (significance based on Principal Investigator's judgment)
  • Frequent severe headaches
  • History of scalp conditions such as eczema or seborrheic dermatitis
  • Metal in head (other than in mouth) including shrapnel/surgical clips/welding fragments
  • Implanted medical devices (including pumps and cardiac pacemakers)
  • Pregnancy
  • Acute substance dependence or withdrawal that would affect ability to complete cognitive training
  • Moderately severe to severe depression (as identified on PHQ-9 scale during baseline screening)
  • Other psychological or medical disorders requiring inpatient treatment (as identified during chart review)
  • Presence of a known metabolic or hormonal disorder (such as Cushing's, untreated thyroid dysfunction, or uncontrolled diabetes mellitus defined as a hemoglobin A1c \> 8.0), or significant edema/volume overload - all of which would affect weight

Outcomes

Primary Outcomes

Change in task impulsivity as measured by the NIH Flanker

Time Frame: Change between baseline and Visit 11, Visit 12 (approximately 2 months), and Visit 13 (approximately 4 months)

Differences in the magnitude of change in NIH Flanker Reaction Time (RT) (ms) between active and sham groups from baseline to follow up sessions.

Change in weight

Time Frame: Change between baseline and Visit 12 (approximately 2 months), and Visit 13 (approximately 4 months)

Differences in the magnitude of change in weights (kg) between active and sham tDCS (active from baseline to follow up sessions.

Secondary Outcomes

  • Change in reported impulsivity as measured by the Barratt Impulsiveness Scale (BIS)(Change between baseline and Visit 11, Visit 12 (approximately 2 months), and Visit 13 (approximately 4 months))
  • Change in reported impulsivity as measured by the UPPS-P Impulsive Behavior Scale (UPPS-P)(Change between baseline and Visit 11, Visit 12 (approximately 2 months), and Visit 13 (approximately 4 months))
  • Change in reported binge eating as measured by the Binge Eating Scale (BES)(Change between baseline and Visit 11, Visit 12 (approximately 2 months), and Visit 13 (approximately 4 months))

Study Sites (1)

Loading locations...

Similar Trials